LEVOSULPIRIDE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC N05AL07
UNII JTG7R315LK
EPA CompTox DTXSID0042583

Structure

InChI Key BGRJTUBHPOOWDU-NSHDSACASA-N
Smiles CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H23N3O4S
Molecular Weight 341.43
AlogP 0.56
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 6.0
Polar Surface Area 101.73
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 23.0

Bioactivity

Mechanism of Action Action Reference
Dopamine D2 receptor antagonist ANTAGONIST PubMed
Protein: Dopamine D2 receptor
Description: D(2) dopamine receptor
Organism : Homo sapiens
P14416 ENSG00000149295
Protein: Serotonin 4 (5-HT4) receptor
Description: 5-hydroxytryptamine receptor 4
Organism : Homo sapiens
Q13639 ENSG00000164270
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Lyase
- - - - 38-50
Enzyme Oxidoreductase
- 7680 - - -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor
- - - 15000 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Dopamine receptor
- 170-233 - 7-39 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Serotonin receptor
- - - 27000 -
Assay Description Organism Bioactivity Reference
Evaluated for the inhibition of carbonic anhydrase enzyme at 0.5 g/L concentration None 37.9 %
Evaluated for the inhibition of carbonic anhydrase enzyme at 1.0 g/L concentration None 43.9 %
Evaluated for the inhibition of carbonic anhydrase enzyme at 1.5 g/L concentration None 47.0 %
Evaluated for the inhibition of carbonic anhydrase enzyme at 2.0 g/L concentration None 50.0 %
Binding affinity towards human dopamine D3 receptor by [3H]spiperone displacement. None 88.0 nM
Antagonist required to inhibit Dopamine receptor D2 photoinactivation by 50% with Iodazidoclebopride using [3H]spiperone Canis lupus familiaris 2e-08 nM
Antidopamine activity in vitro by ability to displace [3H]spiperone from rat brain striatal preparations. None 210.0 nM
In vitro ability to inhibit the binding of [3H]spiperone to dopamine receptor D2 in rat striatal membranes. None 210.0 nM
Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement. None 120.0 nM
In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells None 120.0 nM
Inhibitory concentration required for displacing radioligand [3H]SPI from DA D-2 receptor None 170.0 nM
Inhibitory concentration required for displacing radioligand [3H]SPI from DA D-2 receptor None 233.0 nM
Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement. None 51.0 nM
In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells None 51.0 nM
Ability to inhibit the [3H]spiperone binding to striatum Dopamine receptor D2 was determined in rat Rattus norvegicus 39.0 nM
In vitro displacement of [3H]spiperone from the cloned human dopamine receptor D3 stably expressed in CHO cells None 88.0 nM
Compound was evaluated for binding affinity towards DA D-2 receptor using radioligand [3H]SPI None 39.0 nM
Binding affinity towards dopamine receptor D2 using as [3H]-spiperone radioligand. None 29.0 nM
Inhibition of [3H]spiperone binding to rat striatal membrane Dopamine receptor D2 Rattus norvegicus 6.9 nM
Binding affinity towards dopamine receptor D2 by displacing [3H]spiperone radioligand in rat striatum None 20.6 nM
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) None 128.0 nM DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) None 43.0 nM
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 123.0 nM DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 42.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 7.78 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli 3.44 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 18.7 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 6.68 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 30.02 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 2.16 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans 2.98 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -1.77 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 23.62 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 20.34 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.31 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.16 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.16 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.31 %

Related Entries

Cross References

Resources Reference
ChEBI 64119
ChEMBL CHEMBL267044
DrugBank DB16021
DrugCentral 1577
FDA SRS JTG7R315LK
Guide to Pharmacology 958
PubChem 688272
SureChEMBL SCHEMBL70112
ZINC ZINC000000057008
CONTENTS